BFM
ORIC icon

Boothbay Fund Management’s Oric Pharmaceuticals ORIC Stock Holding History

Boothbay Fund Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,957
Closed -$785K – 2532
2026
Q1 		$785K Sell
61,957
-156,653
-72% -$1.78M 0.01% 1078
2025
Q4 		$1.79M Buy
218,610
+107,777
+97% +$1.24M 0.03% 596
2025
Q3 		$1.33M Buy
+110,833
New +$1.17M 0.02% 721
2023
Q2 		– Sell
-20,232
Closed -$115K – 2161
2023
Q1 		$115K Buy
20,232
+9,004
+80% +$47K ﹤0.01% 1887
2022
Q4 		$66.1K Buy
+11,228
New +$37.9K ﹤0.01% 1856

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boothbay Fund Management's ORIC Position: Q2 2026 in Review

Boothbay Fund Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 61,957 shares — an estimated $785K sold.

Boothbay Fund Management first reported a position in ORIC in Q4 2022 and held it in 5 quarters. The position peaked at $1.79M in Q4 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Boothbay Fund Management reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 61,957 Oric Pharmaceuticals shares in Q2 2026, an estimated $785K.
  • Boothbay Fund Management first reported a position in Oric Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Boothbay Fund Management's Oric Pharmaceuticals position peaked at $1.79M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.